Myelofibrosis - PDFSEARCH.IO - Document Search Engine

Myelofibrosis
Results: 65

#	Item
1	HAEMATOLOGY AUDIT TEMPLATE Add to Reading List Source URL: www.bcshguidelines.com Language: English - Date: 2015-09-20 08:20:56 Myelofibrosis Janus kinase inhibitor Splenomegaly Myeloproliferative neoplasm Ruxolitinib Medical diagnosis Polycythemia vera
2	Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016 Add to Reading List Source URL: www.geron.com Language: English - Date: 2016-04-17 19:35:18 Telomeres Gerontology Stem cells Ageing DNA replication Telomerase Geron Corporation Myelodysplastic syndrome Acute myeloid leukemia Janus kinase inhibitor Lenalidomide Myelofibrosis
3	1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62 Add to Reading List Source URL: whobluebooks.iarc.fr Language: English - Date: 2015-10-29 10:08:25 Medicine Clinical medicine Lymphatic system Stem cells Medical terminology Myelofibrosis Hematology Transplantation medicine Myeloproliferative neoplasm Essential thrombocytosis Thrombocytosis Fibrosis
4	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard Add to Reading List Source URL: www.promedior.com Language: English - Date: 2015-02-08 17:25:15 Myelofibrosis Essential thrombocytosis Myeloproliferative disease Plateletpheresis Ruxolitinib Megakaryocyte Platelet Bone marrow Anemia Medicine Biology Anatomy
5	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Add to Reading List Source URL: www.novartis.ca Language: English - Date: 2015-05-13 10:22:06 Myelofibrosis Janus kinase inhibitor Essential thrombocytosis Thrombocytosis Splenomegaly Polycythemia vera Myeloproliferative disease Thrombocytopenia TG101348 Medicine Hematopathology Ruxolitinib
6	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre Add to Reading List Source URL: www.promedior.com Language: English - Date: 2014-06-13 01:07:42 Polycythemia vera Essential thrombocytosis Fibrosis Medicine Myeloproliferative disease Myelofibrosis
7	670 Vol. 24, No. 9 September 2002 Comments? Questions? Email: Web: VetLearn.com • Fax: Add to Reading List Source URL: www.2ndchance.info Language: English - Date: 2014-02-04 14:24:27 Hematopoiesis Histology Leukocytes Stem cells Blood cells Bone marrow examination Myelofibrosis Hematopoietic stem cell Myelodysplastic syndrome Anatomy Medicine Biology
8	PDF Document Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:56:24 Medical statistics Design of experiments Evaluation methods Ruxolitinib Essential thrombocytosis Polycythemia vera Myelofibrosis Thrombocytosis Clinical trial Medicine Pharmacology Clinical research
9	New York State Cancer Registry Guide to Determine Reportability for Physician Medical Practices Add to Reading List Source URL: www.health.ny.gov Language: English - Date: 2011-04-06 14:08:05 International Classification of Diseases for Oncology Myeloproliferative disease ICD-10 Chapter II: Neoplasms Benign tumor Myelofibrosis Carcinoma Neuroendocrine tumor Myelodysplastic syndrome Carcinoid Medicine Oncology Anatomical pathology
10	Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13) Add to Reading List Source URL: www.scottishmedicines.org.uk Language: English NHS Scotland Pharmacology Pharmacy Clinical pharmacology Scottish Medicines Consortium Myelofibrosis Ruxolitinib Pharmaceuticals policy Formulary Medicine Health Pharmaceutical sciences